Validation of the CSRFENCE score for prediction of febrile neutropenia during chemotherapy cycles 2–6
Purpose Though febrile neutropenia (FN) risk prediction models are important in clinical practice, their external validation is limited. In this study, we validated the Cycle-Specific Risk of FEbrile Neutropenia after ChEmotherapy (CSRFENCE) score for predicting FN. Methods We reviewed the medical r...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Zatarah, Razan [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2022 |
|---|
| Schlagwörter: |
|---|
| Anmerkung: |
© The Author(s) 2022 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Hormones and cancer - New York, NY [u.a.] : Springer, 2010, 13(2022), 1 vom: 17. Okt. |
|---|---|
| Übergeordnetes Werk: |
volume:13 ; year:2022 ; number:1 ; day:17 ; month:10 |
| Links: |
|---|
| DOI / URN: |
10.1007/s12672-022-00575-1 |
|---|
| Katalog-ID: |
SPR048380172 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR048380172 | ||
| 003 | DE-627 | ||
| 005 | 20230509114023.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 221018s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12672-022-00575-1 |2 doi | |
| 035 | |a (DE-627)SPR048380172 | ||
| 035 | |a (SPR)s12672-022-00575-1-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zatarah, Razan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Validation of the CSRFENCE score for prediction of febrile neutropenia during chemotherapy cycles 2–6 |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2022 | ||
| 520 | |a Purpose Though febrile neutropenia (FN) risk prediction models are important in clinical practice, their external validation is limited. In this study, we validated the Cycle-Specific Risk of FEbrile Neutropenia after ChEmotherapy (CSRFENCE) score for predicting FN. Methods We reviewed the medical records of patients with solid malignancies and diffuse large B-cell lymphoma during chemotherapy cycles 2–6 and recorded if patients developed FN, defined as absolute neutrophil counts less than 500 cells/microL with fever more than or equal to 38.2 ℃. The CSRFENCE score was determined by adding the risk factors' coefficients described by the original study; subsequently, the score was used to classify chemotherapy cycles into the following risk groups for developing FN: low, intermediate, high, and very high risk. The discriminatory ability of the score was assessed using area under the receiver operating characteristics curve (AUROCC) and incidence rate ratios (IRR) within each CSRFENCE risk group. Results We analyzed 2870 chemotherapy cycles, of which 42 (1.5%) were associated with FN. Among those, 3 (7.1%), 14 (33.3%), 5 (12%), and 20 (47.6%) were classified as low, intermediate, high, and very high risk for developing FN, respectively. The AUROCC was 0.72 (95% CI 0.64–0.81). Compared with the low risk group (n = 666), the IRR of developing FN was 1.01 (95% CI 0.15–43.37), 0.69 (95% CI 0.08–32.46) and 1.17 (95% CI 0.17–49.49) in the intermediate (n = 1431), high (n = 498) and very high (n = 275) risk groups, respectively. Conclusion The CSRFENCE model can moderately stratify patients into four risk groups for predicting FN prior to chemotherapy cycles 2–6. | ||
| 650 | 4 | |a Chemotherapy-induced febrile neutropenia |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Chemotherapy |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Febrile neutropenia |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Neoplasms |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Prediction |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Faqeer, Nour |4 aut | |
| 700 | 1 | |a Mahmoud, Aseel |4 aut | |
| 700 | 1 | |a Quraan, Tasnim |4 aut | |
| 700 | 1 | |a Matalka, Lujain |4 aut | |
| 700 | 1 | |a Kamal, Aya |4 aut | |
| 700 | 1 | |a Nazer, Lama |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Hormones and cancer |d New York, NY [u.a.] : Springer, 2010 |g 13(2022), 1 vom: 17. Okt. |w (DE-627)621547379 |w (DE-600)2543318-0 |x 1868-8500 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2022 |g number:1 |g day:17 |g month:10 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s12672-022-00575-1 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a GBV_ILN_120 | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2022 |e 1 |b 17 |c 10 | ||
| author_variant |
r z rz n f nf a m am t q tq l m lm a k ak l n ln |
|---|---|
| matchkey_str |
article:18688500:2022----::aiainfhcrecsoeopeitoofbieetoeid |
| hierarchy_sort_str |
2022 |
| publishDate |
2022 |
| allfields |
10.1007/s12672-022-00575-1 doi (DE-627)SPR048380172 (SPR)s12672-022-00575-1-e DE-627 ger DE-627 rakwb eng Zatarah, Razan verfasserin aut Validation of the CSRFENCE score for prediction of febrile neutropenia during chemotherapy cycles 2–6 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2022 Purpose Though febrile neutropenia (FN) risk prediction models are important in clinical practice, their external validation is limited. In this study, we validated the Cycle-Specific Risk of FEbrile Neutropenia after ChEmotherapy (CSRFENCE) score for predicting FN. Methods We reviewed the medical records of patients with solid malignancies and diffuse large B-cell lymphoma during chemotherapy cycles 2–6 and recorded if patients developed FN, defined as absolute neutrophil counts less than 500 cells/microL with fever more than or equal to 38.2 ℃. The CSRFENCE score was determined by adding the risk factors' coefficients described by the original study; subsequently, the score was used to classify chemotherapy cycles into the following risk groups for developing FN: low, intermediate, high, and very high risk. The discriminatory ability of the score was assessed using area under the receiver operating characteristics curve (AUROCC) and incidence rate ratios (IRR) within each CSRFENCE risk group. Results We analyzed 2870 chemotherapy cycles, of which 42 (1.5%) were associated with FN. Among those, 3 (7.1%), 14 (33.3%), 5 (12%), and 20 (47.6%) were classified as low, intermediate, high, and very high risk for developing FN, respectively. The AUROCC was 0.72 (95% CI 0.64–0.81). Compared with the low risk group (n = 666), the IRR of developing FN was 1.01 (95% CI 0.15–43.37), 0.69 (95% CI 0.08–32.46) and 1.17 (95% CI 0.17–49.49) in the intermediate (n = 1431), high (n = 498) and very high (n = 275) risk groups, respectively. Conclusion The CSRFENCE model can moderately stratify patients into four risk groups for predicting FN prior to chemotherapy cycles 2–6. Chemotherapy-induced febrile neutropenia (dpeaa)DE-He213 Chemotherapy (dpeaa)DE-He213 Febrile neutropenia (dpeaa)DE-He213 Neoplasms (dpeaa)DE-He213 Prediction (dpeaa)DE-He213 Faqeer, Nour aut Mahmoud, Aseel aut Quraan, Tasnim aut Matalka, Lujain aut Kamal, Aya aut Nazer, Lama aut Enthalten in Hormones and cancer New York, NY [u.a.] : Springer, 2010 13(2022), 1 vom: 17. Okt. (DE-627)621547379 (DE-600)2543318-0 1868-8500 nnns volume:13 year:2022 number:1 day:17 month:10 https://dx.doi.org/10.1007/s12672-022-00575-1 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_120 AR 13 2022 1 17 10 |
| spelling |
10.1007/s12672-022-00575-1 doi (DE-627)SPR048380172 (SPR)s12672-022-00575-1-e DE-627 ger DE-627 rakwb eng Zatarah, Razan verfasserin aut Validation of the CSRFENCE score for prediction of febrile neutropenia during chemotherapy cycles 2–6 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2022 Purpose Though febrile neutropenia (FN) risk prediction models are important in clinical practice, their external validation is limited. In this study, we validated the Cycle-Specific Risk of FEbrile Neutropenia after ChEmotherapy (CSRFENCE) score for predicting FN. Methods We reviewed the medical records of patients with solid malignancies and diffuse large B-cell lymphoma during chemotherapy cycles 2–6 and recorded if patients developed FN, defined as absolute neutrophil counts less than 500 cells/microL with fever more than or equal to 38.2 ℃. The CSRFENCE score was determined by adding the risk factors' coefficients described by the original study; subsequently, the score was used to classify chemotherapy cycles into the following risk groups for developing FN: low, intermediate, high, and very high risk. The discriminatory ability of the score was assessed using area under the receiver operating characteristics curve (AUROCC) and incidence rate ratios (IRR) within each CSRFENCE risk group. Results We analyzed 2870 chemotherapy cycles, of which 42 (1.5%) were associated with FN. Among those, 3 (7.1%), 14 (33.3%), 5 (12%), and 20 (47.6%) were classified as low, intermediate, high, and very high risk for developing FN, respectively. The AUROCC was 0.72 (95% CI 0.64–0.81). Compared with the low risk group (n = 666), the IRR of developing FN was 1.01 (95% CI 0.15–43.37), 0.69 (95% CI 0.08–32.46) and 1.17 (95% CI 0.17–49.49) in the intermediate (n = 1431), high (n = 498) and very high (n = 275) risk groups, respectively. Conclusion The CSRFENCE model can moderately stratify patients into four risk groups for predicting FN prior to chemotherapy cycles 2–6. Chemotherapy-induced febrile neutropenia (dpeaa)DE-He213 Chemotherapy (dpeaa)DE-He213 Febrile neutropenia (dpeaa)DE-He213 Neoplasms (dpeaa)DE-He213 Prediction (dpeaa)DE-He213 Faqeer, Nour aut Mahmoud, Aseel aut Quraan, Tasnim aut Matalka, Lujain aut Kamal, Aya aut Nazer, Lama aut Enthalten in Hormones and cancer New York, NY [u.a.] : Springer, 2010 13(2022), 1 vom: 17. Okt. (DE-627)621547379 (DE-600)2543318-0 1868-8500 nnns volume:13 year:2022 number:1 day:17 month:10 https://dx.doi.org/10.1007/s12672-022-00575-1 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_120 AR 13 2022 1 17 10 |
| allfields_unstemmed |
10.1007/s12672-022-00575-1 doi (DE-627)SPR048380172 (SPR)s12672-022-00575-1-e DE-627 ger DE-627 rakwb eng Zatarah, Razan verfasserin aut Validation of the CSRFENCE score for prediction of febrile neutropenia during chemotherapy cycles 2–6 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2022 Purpose Though febrile neutropenia (FN) risk prediction models are important in clinical practice, their external validation is limited. In this study, we validated the Cycle-Specific Risk of FEbrile Neutropenia after ChEmotherapy (CSRFENCE) score for predicting FN. Methods We reviewed the medical records of patients with solid malignancies and diffuse large B-cell lymphoma during chemotherapy cycles 2–6 and recorded if patients developed FN, defined as absolute neutrophil counts less than 500 cells/microL with fever more than or equal to 38.2 ℃. The CSRFENCE score was determined by adding the risk factors' coefficients described by the original study; subsequently, the score was used to classify chemotherapy cycles into the following risk groups for developing FN: low, intermediate, high, and very high risk. The discriminatory ability of the score was assessed using area under the receiver operating characteristics curve (AUROCC) and incidence rate ratios (IRR) within each CSRFENCE risk group. Results We analyzed 2870 chemotherapy cycles, of which 42 (1.5%) were associated with FN. Among those, 3 (7.1%), 14 (33.3%), 5 (12%), and 20 (47.6%) were classified as low, intermediate, high, and very high risk for developing FN, respectively. The AUROCC was 0.72 (95% CI 0.64–0.81). Compared with the low risk group (n = 666), the IRR of developing FN was 1.01 (95% CI 0.15–43.37), 0.69 (95% CI 0.08–32.46) and 1.17 (95% CI 0.17–49.49) in the intermediate (n = 1431), high (n = 498) and very high (n = 275) risk groups, respectively. Conclusion The CSRFENCE model can moderately stratify patients into four risk groups for predicting FN prior to chemotherapy cycles 2–6. Chemotherapy-induced febrile neutropenia (dpeaa)DE-He213 Chemotherapy (dpeaa)DE-He213 Febrile neutropenia (dpeaa)DE-He213 Neoplasms (dpeaa)DE-He213 Prediction (dpeaa)DE-He213 Faqeer, Nour aut Mahmoud, Aseel aut Quraan, Tasnim aut Matalka, Lujain aut Kamal, Aya aut Nazer, Lama aut Enthalten in Hormones and cancer New York, NY [u.a.] : Springer, 2010 13(2022), 1 vom: 17. Okt. (DE-627)621547379 (DE-600)2543318-0 1868-8500 nnns volume:13 year:2022 number:1 day:17 month:10 https://dx.doi.org/10.1007/s12672-022-00575-1 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_120 AR 13 2022 1 17 10 |
| allfieldsGer |
10.1007/s12672-022-00575-1 doi (DE-627)SPR048380172 (SPR)s12672-022-00575-1-e DE-627 ger DE-627 rakwb eng Zatarah, Razan verfasserin aut Validation of the CSRFENCE score for prediction of febrile neutropenia during chemotherapy cycles 2–6 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2022 Purpose Though febrile neutropenia (FN) risk prediction models are important in clinical practice, their external validation is limited. In this study, we validated the Cycle-Specific Risk of FEbrile Neutropenia after ChEmotherapy (CSRFENCE) score for predicting FN. Methods We reviewed the medical records of patients with solid malignancies and diffuse large B-cell lymphoma during chemotherapy cycles 2–6 and recorded if patients developed FN, defined as absolute neutrophil counts less than 500 cells/microL with fever more than or equal to 38.2 ℃. The CSRFENCE score was determined by adding the risk factors' coefficients described by the original study; subsequently, the score was used to classify chemotherapy cycles into the following risk groups for developing FN: low, intermediate, high, and very high risk. The discriminatory ability of the score was assessed using area under the receiver operating characteristics curve (AUROCC) and incidence rate ratios (IRR) within each CSRFENCE risk group. Results We analyzed 2870 chemotherapy cycles, of which 42 (1.5%) were associated with FN. Among those, 3 (7.1%), 14 (33.3%), 5 (12%), and 20 (47.6%) were classified as low, intermediate, high, and very high risk for developing FN, respectively. The AUROCC was 0.72 (95% CI 0.64–0.81). Compared with the low risk group (n = 666), the IRR of developing FN was 1.01 (95% CI 0.15–43.37), 0.69 (95% CI 0.08–32.46) and 1.17 (95% CI 0.17–49.49) in the intermediate (n = 1431), high (n = 498) and very high (n = 275) risk groups, respectively. Conclusion The CSRFENCE model can moderately stratify patients into four risk groups for predicting FN prior to chemotherapy cycles 2–6. Chemotherapy-induced febrile neutropenia (dpeaa)DE-He213 Chemotherapy (dpeaa)DE-He213 Febrile neutropenia (dpeaa)DE-He213 Neoplasms (dpeaa)DE-He213 Prediction (dpeaa)DE-He213 Faqeer, Nour aut Mahmoud, Aseel aut Quraan, Tasnim aut Matalka, Lujain aut Kamal, Aya aut Nazer, Lama aut Enthalten in Hormones and cancer New York, NY [u.a.] : Springer, 2010 13(2022), 1 vom: 17. Okt. (DE-627)621547379 (DE-600)2543318-0 1868-8500 nnns volume:13 year:2022 number:1 day:17 month:10 https://dx.doi.org/10.1007/s12672-022-00575-1 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_120 AR 13 2022 1 17 10 |
| allfieldsSound |
10.1007/s12672-022-00575-1 doi (DE-627)SPR048380172 (SPR)s12672-022-00575-1-e DE-627 ger DE-627 rakwb eng Zatarah, Razan verfasserin aut Validation of the CSRFENCE score for prediction of febrile neutropenia during chemotherapy cycles 2–6 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2022 Purpose Though febrile neutropenia (FN) risk prediction models are important in clinical practice, their external validation is limited. In this study, we validated the Cycle-Specific Risk of FEbrile Neutropenia after ChEmotherapy (CSRFENCE) score for predicting FN. Methods We reviewed the medical records of patients with solid malignancies and diffuse large B-cell lymphoma during chemotherapy cycles 2–6 and recorded if patients developed FN, defined as absolute neutrophil counts less than 500 cells/microL with fever more than or equal to 38.2 ℃. The CSRFENCE score was determined by adding the risk factors' coefficients described by the original study; subsequently, the score was used to classify chemotherapy cycles into the following risk groups for developing FN: low, intermediate, high, and very high risk. The discriminatory ability of the score was assessed using area under the receiver operating characteristics curve (AUROCC) and incidence rate ratios (IRR) within each CSRFENCE risk group. Results We analyzed 2870 chemotherapy cycles, of which 42 (1.5%) were associated with FN. Among those, 3 (7.1%), 14 (33.3%), 5 (12%), and 20 (47.6%) were classified as low, intermediate, high, and very high risk for developing FN, respectively. The AUROCC was 0.72 (95% CI 0.64–0.81). Compared with the low risk group (n = 666), the IRR of developing FN was 1.01 (95% CI 0.15–43.37), 0.69 (95% CI 0.08–32.46) and 1.17 (95% CI 0.17–49.49) in the intermediate (n = 1431), high (n = 498) and very high (n = 275) risk groups, respectively. Conclusion The CSRFENCE model can moderately stratify patients into four risk groups for predicting FN prior to chemotherapy cycles 2–6. Chemotherapy-induced febrile neutropenia (dpeaa)DE-He213 Chemotherapy (dpeaa)DE-He213 Febrile neutropenia (dpeaa)DE-He213 Neoplasms (dpeaa)DE-He213 Prediction (dpeaa)DE-He213 Faqeer, Nour aut Mahmoud, Aseel aut Quraan, Tasnim aut Matalka, Lujain aut Kamal, Aya aut Nazer, Lama aut Enthalten in Hormones and cancer New York, NY [u.a.] : Springer, 2010 13(2022), 1 vom: 17. Okt. (DE-627)621547379 (DE-600)2543318-0 1868-8500 nnns volume:13 year:2022 number:1 day:17 month:10 https://dx.doi.org/10.1007/s12672-022-00575-1 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_120 AR 13 2022 1 17 10 |
| language |
English |
| source |
Enthalten in Hormones and cancer 13(2022), 1 vom: 17. Okt. volume:13 year:2022 number:1 day:17 month:10 |
| sourceStr |
Enthalten in Hormones and cancer 13(2022), 1 vom: 17. Okt. volume:13 year:2022 number:1 day:17 month:10 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Chemotherapy-induced febrile neutropenia Chemotherapy Febrile neutropenia Neoplasms Prediction |
| isfreeaccess_bool |
true |
| container_title |
Hormones and cancer |
| authorswithroles_txt_mv |
Zatarah, Razan @@aut@@ Faqeer, Nour @@aut@@ Mahmoud, Aseel @@aut@@ Quraan, Tasnim @@aut@@ Matalka, Lujain @@aut@@ Kamal, Aya @@aut@@ Nazer, Lama @@aut@@ |
| publishDateDaySort_date |
2022-10-17T00:00:00Z |
| hierarchy_top_id |
621547379 |
| id |
SPR048380172 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR048380172</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230509114023.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">221018s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s12672-022-00575-1</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR048380172</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s12672-022-00575-1-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Zatarah, Razan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Validation of the CSRFENCE score for prediction of febrile neutropenia during chemotherapy cycles 2–6</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© The Author(s) 2022</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Purpose Though febrile neutropenia (FN) risk prediction models are important in clinical practice, their external validation is limited. In this study, we validated the Cycle-Specific Risk of FEbrile Neutropenia after ChEmotherapy (CSRFENCE) score for predicting FN. Methods We reviewed the medical records of patients with solid malignancies and diffuse large B-cell lymphoma during chemotherapy cycles 2–6 and recorded if patients developed FN, defined as absolute neutrophil counts less than 500 cells/microL with fever more than or equal to 38.2 ℃. The CSRFENCE score was determined by adding the risk factors' coefficients described by the original study; subsequently, the score was used to classify chemotherapy cycles into the following risk groups for developing FN: low, intermediate, high, and very high risk. The discriminatory ability of the score was assessed using area under the receiver operating characteristics curve (AUROCC) and incidence rate ratios (IRR) within each CSRFENCE risk group. Results We analyzed 2870 chemotherapy cycles, of which 42 (1.5%) were associated with FN. Among those, 3 (7.1%), 14 (33.3%), 5 (12%), and 20 (47.6%) were classified as low, intermediate, high, and very high risk for developing FN, respectively. The AUROCC was 0.72 (95% CI 0.64–0.81). Compared with the low risk group (n = 666), the IRR of developing FN was 1.01 (95% CI 0.15–43.37), 0.69 (95% CI 0.08–32.46) and 1.17 (95% CI 0.17–49.49) in the intermediate (n = 1431), high (n = 498) and very high (n = 275) risk groups, respectively. Conclusion The CSRFENCE model can moderately stratify patients into four risk groups for predicting FN prior to chemotherapy cycles 2–6.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Chemotherapy-induced febrile neutropenia</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Chemotherapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Febrile neutropenia</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neoplasms</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Prediction</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Faqeer, Nour</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mahmoud, Aseel</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Quraan, Tasnim</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Matalka, Lujain</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kamal, Aya</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nazer, Lama</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Hormones and cancer</subfield><subfield code="d">New York, NY [u.a.] : Springer, 2010</subfield><subfield code="g">13(2022), 1 vom: 17. Okt.</subfield><subfield code="w">(DE-627)621547379</subfield><subfield code="w">(DE-600)2543318-0</subfield><subfield code="x">1868-8500</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:13</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:1</subfield><subfield code="g">day:17</subfield><subfield code="g">month:10</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s12672-022-00575-1</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">13</subfield><subfield code="j">2022</subfield><subfield code="e">1</subfield><subfield code="b">17</subfield><subfield code="c">10</subfield></datafield></record></collection>
|
| author |
Zatarah, Razan |
| spellingShingle |
Zatarah, Razan misc Chemotherapy-induced febrile neutropenia misc Chemotherapy misc Febrile neutropenia misc Neoplasms misc Prediction Validation of the CSRFENCE score for prediction of febrile neutropenia during chemotherapy cycles 2–6 |
| authorStr |
Zatarah, Razan |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)621547379 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1868-8500 |
| topic_title |
Validation of the CSRFENCE score for prediction of febrile neutropenia during chemotherapy cycles 2–6 Chemotherapy-induced febrile neutropenia (dpeaa)DE-He213 Chemotherapy (dpeaa)DE-He213 Febrile neutropenia (dpeaa)DE-He213 Neoplasms (dpeaa)DE-He213 Prediction (dpeaa)DE-He213 |
| topic |
misc Chemotherapy-induced febrile neutropenia misc Chemotherapy misc Febrile neutropenia misc Neoplasms misc Prediction |
| topic_unstemmed |
misc Chemotherapy-induced febrile neutropenia misc Chemotherapy misc Febrile neutropenia misc Neoplasms misc Prediction |
| topic_browse |
misc Chemotherapy-induced febrile neutropenia misc Chemotherapy misc Febrile neutropenia misc Neoplasms misc Prediction |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Hormones and cancer |
| hierarchy_parent_id |
621547379 |
| hierarchy_top_title |
Hormones and cancer |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)621547379 (DE-600)2543318-0 |
| title |
Validation of the CSRFENCE score for prediction of febrile neutropenia during chemotherapy cycles 2–6 |
| ctrlnum |
(DE-627)SPR048380172 (SPR)s12672-022-00575-1-e |
| title_full |
Validation of the CSRFENCE score for prediction of febrile neutropenia during chemotherapy cycles 2–6 |
| author_sort |
Zatarah, Razan |
| journal |
Hormones and cancer |
| journalStr |
Hormones and cancer |
| lang_code |
eng |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2022 |
| contenttype_str_mv |
txt |
| author_browse |
Zatarah, Razan Faqeer, Nour Mahmoud, Aseel Quraan, Tasnim Matalka, Lujain Kamal, Aya Nazer, Lama |
| container_volume |
13 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Zatarah, Razan |
| doi_str_mv |
10.1007/s12672-022-00575-1 |
| title_sort |
validation of the csrfence score for prediction of febrile neutropenia during chemotherapy cycles 2–6 |
| title_auth |
Validation of the CSRFENCE score for prediction of febrile neutropenia during chemotherapy cycles 2–6 |
| abstract |
Purpose Though febrile neutropenia (FN) risk prediction models are important in clinical practice, their external validation is limited. In this study, we validated the Cycle-Specific Risk of FEbrile Neutropenia after ChEmotherapy (CSRFENCE) score for predicting FN. Methods We reviewed the medical records of patients with solid malignancies and diffuse large B-cell lymphoma during chemotherapy cycles 2–6 and recorded if patients developed FN, defined as absolute neutrophil counts less than 500 cells/microL with fever more than or equal to 38.2 ℃. The CSRFENCE score was determined by adding the risk factors' coefficients described by the original study; subsequently, the score was used to classify chemotherapy cycles into the following risk groups for developing FN: low, intermediate, high, and very high risk. The discriminatory ability of the score was assessed using area under the receiver operating characteristics curve (AUROCC) and incidence rate ratios (IRR) within each CSRFENCE risk group. Results We analyzed 2870 chemotherapy cycles, of which 42 (1.5%) were associated with FN. Among those, 3 (7.1%), 14 (33.3%), 5 (12%), and 20 (47.6%) were classified as low, intermediate, high, and very high risk for developing FN, respectively. The AUROCC was 0.72 (95% CI 0.64–0.81). Compared with the low risk group (n = 666), the IRR of developing FN was 1.01 (95% CI 0.15–43.37), 0.69 (95% CI 0.08–32.46) and 1.17 (95% CI 0.17–49.49) in the intermediate (n = 1431), high (n = 498) and very high (n = 275) risk groups, respectively. Conclusion The CSRFENCE model can moderately stratify patients into four risk groups for predicting FN prior to chemotherapy cycles 2–6. © The Author(s) 2022 |
| abstractGer |
Purpose Though febrile neutropenia (FN) risk prediction models are important in clinical practice, their external validation is limited. In this study, we validated the Cycle-Specific Risk of FEbrile Neutropenia after ChEmotherapy (CSRFENCE) score for predicting FN. Methods We reviewed the medical records of patients with solid malignancies and diffuse large B-cell lymphoma during chemotherapy cycles 2–6 and recorded if patients developed FN, defined as absolute neutrophil counts less than 500 cells/microL with fever more than or equal to 38.2 ℃. The CSRFENCE score was determined by adding the risk factors' coefficients described by the original study; subsequently, the score was used to classify chemotherapy cycles into the following risk groups for developing FN: low, intermediate, high, and very high risk. The discriminatory ability of the score was assessed using area under the receiver operating characteristics curve (AUROCC) and incidence rate ratios (IRR) within each CSRFENCE risk group. Results We analyzed 2870 chemotherapy cycles, of which 42 (1.5%) were associated with FN. Among those, 3 (7.1%), 14 (33.3%), 5 (12%), and 20 (47.6%) were classified as low, intermediate, high, and very high risk for developing FN, respectively. The AUROCC was 0.72 (95% CI 0.64–0.81). Compared with the low risk group (n = 666), the IRR of developing FN was 1.01 (95% CI 0.15–43.37), 0.69 (95% CI 0.08–32.46) and 1.17 (95% CI 0.17–49.49) in the intermediate (n = 1431), high (n = 498) and very high (n = 275) risk groups, respectively. Conclusion The CSRFENCE model can moderately stratify patients into four risk groups for predicting FN prior to chemotherapy cycles 2–6. © The Author(s) 2022 |
| abstract_unstemmed |
Purpose Though febrile neutropenia (FN) risk prediction models are important in clinical practice, their external validation is limited. In this study, we validated the Cycle-Specific Risk of FEbrile Neutropenia after ChEmotherapy (CSRFENCE) score for predicting FN. Methods We reviewed the medical records of patients with solid malignancies and diffuse large B-cell lymphoma during chemotherapy cycles 2–6 and recorded if patients developed FN, defined as absolute neutrophil counts less than 500 cells/microL with fever more than or equal to 38.2 ℃. The CSRFENCE score was determined by adding the risk factors' coefficients described by the original study; subsequently, the score was used to classify chemotherapy cycles into the following risk groups for developing FN: low, intermediate, high, and very high risk. The discriminatory ability of the score was assessed using area under the receiver operating characteristics curve (AUROCC) and incidence rate ratios (IRR) within each CSRFENCE risk group. Results We analyzed 2870 chemotherapy cycles, of which 42 (1.5%) were associated with FN. Among those, 3 (7.1%), 14 (33.3%), 5 (12%), and 20 (47.6%) were classified as low, intermediate, high, and very high risk for developing FN, respectively. The AUROCC was 0.72 (95% CI 0.64–0.81). Compared with the low risk group (n = 666), the IRR of developing FN was 1.01 (95% CI 0.15–43.37), 0.69 (95% CI 0.08–32.46) and 1.17 (95% CI 0.17–49.49) in the intermediate (n = 1431), high (n = 498) and very high (n = 275) risk groups, respectively. Conclusion The CSRFENCE model can moderately stratify patients into four risk groups for predicting FN prior to chemotherapy cycles 2–6. © The Author(s) 2022 |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_120 |
| container_issue |
1 |
| title_short |
Validation of the CSRFENCE score for prediction of febrile neutropenia during chemotherapy cycles 2–6 |
| url |
https://dx.doi.org/10.1007/s12672-022-00575-1 |
| remote_bool |
true |
| author2 |
Faqeer, Nour Mahmoud, Aseel Quraan, Tasnim Matalka, Lujain Kamal, Aya Nazer, Lama |
| author2Str |
Faqeer, Nour Mahmoud, Aseel Quraan, Tasnim Matalka, Lujain Kamal, Aya Nazer, Lama |
| ppnlink |
621547379 |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.1007/s12672-022-00575-1 |
| up_date |
2024-07-03T18:50:09.837Z |
| _version_ |
1803584913934385152 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR048380172</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230509114023.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">221018s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s12672-022-00575-1</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR048380172</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s12672-022-00575-1-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Zatarah, Razan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Validation of the CSRFENCE score for prediction of febrile neutropenia during chemotherapy cycles 2–6</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© The Author(s) 2022</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Purpose Though febrile neutropenia (FN) risk prediction models are important in clinical practice, their external validation is limited. In this study, we validated the Cycle-Specific Risk of FEbrile Neutropenia after ChEmotherapy (CSRFENCE) score for predicting FN. Methods We reviewed the medical records of patients with solid malignancies and diffuse large B-cell lymphoma during chemotherapy cycles 2–6 and recorded if patients developed FN, defined as absolute neutrophil counts less than 500 cells/microL with fever more than or equal to 38.2 ℃. The CSRFENCE score was determined by adding the risk factors' coefficients described by the original study; subsequently, the score was used to classify chemotherapy cycles into the following risk groups for developing FN: low, intermediate, high, and very high risk. The discriminatory ability of the score was assessed using area under the receiver operating characteristics curve (AUROCC) and incidence rate ratios (IRR) within each CSRFENCE risk group. Results We analyzed 2870 chemotherapy cycles, of which 42 (1.5%) were associated with FN. Among those, 3 (7.1%), 14 (33.3%), 5 (12%), and 20 (47.6%) were classified as low, intermediate, high, and very high risk for developing FN, respectively. The AUROCC was 0.72 (95% CI 0.64–0.81). Compared with the low risk group (n = 666), the IRR of developing FN was 1.01 (95% CI 0.15–43.37), 0.69 (95% CI 0.08–32.46) and 1.17 (95% CI 0.17–49.49) in the intermediate (n = 1431), high (n = 498) and very high (n = 275) risk groups, respectively. Conclusion The CSRFENCE model can moderately stratify patients into four risk groups for predicting FN prior to chemotherapy cycles 2–6.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Chemotherapy-induced febrile neutropenia</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Chemotherapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Febrile neutropenia</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neoplasms</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Prediction</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Faqeer, Nour</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mahmoud, Aseel</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Quraan, Tasnim</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Matalka, Lujain</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kamal, Aya</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nazer, Lama</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Hormones and cancer</subfield><subfield code="d">New York, NY [u.a.] : Springer, 2010</subfield><subfield code="g">13(2022), 1 vom: 17. Okt.</subfield><subfield code="w">(DE-627)621547379</subfield><subfield code="w">(DE-600)2543318-0</subfield><subfield code="x">1868-8500</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:13</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:1</subfield><subfield code="g">day:17</subfield><subfield code="g">month:10</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s12672-022-00575-1</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">13</subfield><subfield code="j">2022</subfield><subfield code="e">1</subfield><subfield code="b">17</subfield><subfield code="c">10</subfield></datafield></record></collection>
|
| score |
7.399081 |